SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Sign in front of Pfizer in Quebec, Canada
Cancer
Pfizer Sees Path to Braftovi’s Full Approval With Phase III CRC Data
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the way for its full approval for the treatment of certain colorectal cancers, according to the company.
February 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, according to analysts.
February 3, 2025
 · 
3 min read
 · 
Tristan Manalac
Cosmetologist does injections on the lips and on the face of a beautiful woman in a beauty salon. Cosmetology concept.
Earnings
AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.
February 3, 2025
 · 
4 min read
 · 
Annalee Armstrong
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Indivior, SpringWorks, More
The rare disease space is awaiting two FDA verdicts in February, one for a genetic disease and another for a non-malignant tumor.
February 3, 2025
 · 
5 min read
 · 
Tristan Manalac
3D illustration of neurons
Opinion
Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease.
February 3, 2025
 · 
3 min read
 · 
Jia Jie Chen
Pictured: FDA headquarters with money and pill bottles
FDA
What Trump’s Second Term Could Mean for PDUFA’s Future
Robert F. Kennedy, Jr.—Trump’s pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA, particularly financial links between the two, which could indicate trouble for the user-fee model.
February 3, 2025
 · 
4 min read
 · 
Ben Hargreaves
Human hands symbolizing teamwork working on a pie chart with ai symbol in it. Arms point fingers hold pieces diagram chart. Distribute AI stock options on the market.
Earnings
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical program to an adjunct approach—for now.
January 31, 2025
 · 
3 min read
 · 
Annalee Armstrong
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
ImmunityBio Continues Trimming Workforce While Working to Advance Anktiva
ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.
January 31, 2025
 · 
1 min read
 · 
Angela Gabriel
External view of the U.S. Capitol building at sunset
IRA
Drug Pricing and the Uncertain Future of the IRA Under Trump
While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug prices in the U.S., Trump has so far been mum on how the controversial law could evolve in the coming years.
January 31, 2025
 · 
4 min read
 · 
Jef Akst
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS